SAN FRANCISCO, April 10, 2017 -- Today Zephyr Health, the leading Insights-as-a-Service company, released a report entitled “Powering the Life Sciences Commercial Engine with Market Access Insights.” Based on results from a survey of 60 industry leaders working in market access, medical affairs, marketing and sales, the report examines the challenges with effective market access data integration between market access and commercial teams, and key opportunities to reengineer the business for the future.
According to this report, all survey respondents recognized the importance of a market access-driven commercial model, and the need to more effectively share data to gain any competitive advantage that a formulary change might offer. In fact, more than 40% of participants cite data integration and sharing as the biggest barrier to collaboration between managed markets and sales and marketing teams. Organizational silos and disparate technology solutions play a significant role in these challenges.
“It’s clear from the survey that the Life Sciences industry still needs solutions for effective pull-through by field sales for market access opportunities created by managed care teams” said Lance Scott, chief executive officer, Zephyr Health. “While pharmaceutical companies have a clear understanding of the power these insights can provide, in terms of commercial success, breaking down silos throughout the organization is essential to data integration of any kind. However, these efforts must be supplemented with technology that disseminates rich and predictive insights across the organization in order to stay ahead of competition.”
The “Powering the Life Sciences Commercial Engine with Market Access Insight” global survey examined the landscape for pharmaceutical companies seeking to bridge the insights gap between market access teams and other commercial functions. For more information, download a copy of the Zephyr Health report.
About Zephyr Health
Zephyr Health helps Life Sciences companies – pharmaceutical, biotech, medical device and diagnostics – engage the right physicians, accounts and institutions using insights from global health data. Zephyr Illuminate™ is a leading Insights-as-a-Service solution that integrates thousands of data sources to create precise and predictive insights. From pre-launch to product maturity, Life Sciences companies can make confident decisions faster with data-driven targeting and deep customer profiles.
Zephyr Health is a privately held company headquartered in San Francisco with offices in London, UK, and Pune, India. Zephyr Health is venture backed by Google Ventures, Kleiner Perkins Caufield & Byers, and Icon Ventures. For more information, please visit: www.zephyrhealth.com.
Media contact for Zephyr Health: [email protected]


American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Washington Post Publisher Will Lewis Steps Down After Layoffs
Instagram Outage Disrupts Thousands of U.S. Users
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 



